ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been rated as one of the top-performing contract research organisations (CRO) for phase 1 clini ...

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic ...

Phase-III trial of indigenous one-shot dengue vaccine by Panacea Biotec shows promising results in India, aiming for ...

Secured approval from the Regulation Agency for Medical and Pharmaceutical Activities (RAMPA) in Georgia for Phase 2B/3 ...

Primary progressive aphasia (PPA) is a rare neurological syndrome that gradually impairs a person’s language. Baycrest Canada ...

Enrolment of about 10,500 participants in the phase III clinical trial of the indigenous one-shot Panacea Biotec developed dengue vaccine, DengiAll, is likely to be completed by October across 20 ...

Rahway, New Jersey Wednesday, July 16, 2025, 17:30 Hrs [IST] ...

FDA Protocol Review Completed ~~ Rho, Inc. Selected as Clinical Research Partner ~ SAN DIEGO, CA / ACCESS Newswire / July 16, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company" ...

A recent study found that only 15% of cancer survivors discussed trials with their healthcare providers, with ...

Verastem Oncology releases primary results from phase 2 RAMP 201 trial of Avutometinib in combo with defactinib: Boston Tuesday, July 15, 2025, 09:00 Hrs [IST] Verastem Oncology, ...

Pfizer has received approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control ...